Such targets should include the proportion of persons accessing CD4 testing, persons with a CD4 count of < 200 cells/μL who are screened for TB and cryptococcal disease, and co-infected persons subsequently started on therapy (Table 1). Here, CD4 is linked to tuberculosis.